Maine warns patients about contaminated Deep Sea cannabis concentrate

State Issues Immediate Recall for Deep Sea Concentrate Line

Maine's Office of Cannabis Policy directed medical dispensaries to pull all Deep Sea concentrate inventory from shelves after myclobutanil residues tested above the state's 0.1 ppm action level. The contaminated batch, identified by lot numbers beginning with DS-092026, was distributed to at least 12 licensed medical dispensaries across Cumberland, York, and Penobscot counties between September 10 and September 17.

Myclobutanil is a systemic fungicide banned in cannabis cultivation under Maine's adult-use and medical rules. When heated, the compound converts to hydrogen cyanide—a known respiratory toxin. State regulators didn't disclose which cultivator supplied the raw material or whether the contamination occurred during cultivation or post-harvest processing.

Patients who purchased Deep Sea products in the past two weeks should check packaging for the DS-092026 lot prefix. Return unused portions to your dispensary for a full refund, according to the alert.

Testing Gap Exposes Vulnerability in Medical Supply Chain

The contamination slipped through Maine's compliance testing system because the state doesn't mandate pesticide screening for all medical cannabis products—only for adult-use inventory sold through recreational retailers. Medical dispensaries operate under a separate regulatory framework that allows voluntary testing protocols, a gap patient advocates have flagged since the state launched its adult-use market in 2020.

The two-tier testing standard creates a safety blind spot for the patients who need the cleanest product the most.

Maine's adult-use rules require full-panel pesticide, heavy metal, and microbial testing for all concentrate products before retail sale. No such blanket requirement exists for medical products unless a dispensary opts into third-party certification. The Deep Sea batch was flagged only after a dispensary in Portland submitted a voluntary sample to a licensed testing laboratory.

For full background on this issue, see the CannIntel topic hub on cannabis product contamination.

What Patients and Dispensaries Should Do Next

The Office of Cannabis Policy directed all licensed medical dispensaries to quarantine Deep Sea inventory and submit batch records to state investigators by September 25. Patients experiencing respiratory symptoms, nausea, or headaches after using Deep Sea concentrates should contact their healthcare provider and file an adverse event report with the state.

Maine regulators haven't yet disclosed whether criminal or administrative penalties will be pursued against the cultivator or manufacturer responsible for the contaminated batch. The state's cannabis enforcement division can levy fines up to $10,000 per violation. It can also suspend or revoke licenses for repeat offenders.

The next signal: whether Maine lawmakers will move to harmonize medical and adult-use testing standards when the legislature reconvenes in January 2027. Patient advocacy groups are already drafting bill language to close the gap.